SCLX

Scilex Holding Company

2.47

Oct 22 • 3:59 PM ET -0.09 (-3.52%)

2.41

Aftermarket • 7:30 PM ET -0.06 (-2.43%)

Healthcare Drug Manufacturers - General USA Nano NASD

Peers: HRTX PCRX TNXP COLL AXSM TLPH AYTU DERM ANIK VRTX

| Held by: VTI VXF IWC CSML BTEC NTKI AVTM

Scroll to Statements

Index	-
Market Cap	17.38M
Enterprise Value	120.61M
Income	-448.35M
Sales	31.61M
Book/sh	-43.83
Cash/sh	0.08
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	34
IPO	Mar 05, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	0.55
P/B	-
P/C	29.96
P/FCF	4.68
EV/EBITDA	-
EV/Sales	3.82
Quick Ratio	0.06
Current Ratio	0.07
Debt/Eq	-
LT Debt/Eq	-
Option/Short	No / Yes

EPS (ttm)	-49.80
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	-81.59% -392.41%
Sales past 3/5Y	-7.35% -
EPS Y/Y TTM	-310.88%
Sales Y/Y TTM	-28.55%
EPS Q/Q	-124.28%
Sales Q/Q	-22.78%
Earnings	-
EPS/Sales Surpr.	0.00% 0.00%

Insider Own	11.67%
Insider Trans	0.00%
Inst Own	9.98%
Inst Trans	-2.96%
ROA	-265.83%
ROE	-
ROIC	-
Gross Margin	29.18%
Oper. Margin	-903.52%
Profit Margin	-1418.45%
SMA20	-27.53%
SMA50	-47.05%
SMA200	-54.99%
Trades

Shs Outstand	7.03M
Shs Float	6.21M
Short Float	2.76%
Short Ratio	3.51
Short Interest	0.17M
52W High	16.81 -85.31%
52W Low	2.51 -1.59%
Volatility	6.57% 9.25%
ATR (14)	0.30
RSI (14)	17.91
Beta	1.73
Rel Volume	0.69
Avg Volume	48.74K
Volume	33,429

Perf Week	-12.41%
Perf Month	-51.57%
Perf Quarter	-63.89%
Perf Half Y	-42.84%
Perf YTD	-67.48%
Perf Year	-69.88%
Perf 3Y	-93.09%
Perf 5Y	-98.87%
Perf 10Y	-
Recom	3.00
Target Price	392.26
Prev Close	2.56
Price	2.47
Change %	-3.52%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-27-25	Initiated	D. Boral Capital	Buy	$22
Oct-16-24	Initiated	Alliance Global Partners	Buy	$14
Jun-13-24	Initiated	Rodman & Renshaw	Buy	$13
Oct-16-23	Initiated	B. Riley Securities	Buy	$4
Oct-13-23	Initiated	B. Riley Securities	Buy	$4
Oct-09-23	Initiated	H.C. Wainwright	Buy	$12

Today 07:40AM	DataMEDS AI Enters Into Amended and Restated LOI to License and Acquire IP that Enables Goal-Driven Prescription Drug Telehealth, Medical Drones and Healthcare Blockchain Technologies (ACCESSWIRE)
Jul-06-26 11:35AM	Scilex Holding Company Announces Dream Bowl I Meme Coin Tokens Commence Trading on the Biconomy Exchange on July 6, 2026 (GlobeNewswire)
08:19AM	Scilex, Vera Therapeutics rise premarket; Strategy gains (Investing.com)
07:33AM	Scilex Shares Jump After Securing $100 Million Strategic Investment Proposal (SCLX) (InvestorsHub)
06:00AM	Scilex Holding Company Announces Signing of Binding Term Sheet for Proposed $100 Million Strategic Investment from iHolding Group LLP (GlobeNewswire)
07:45AM	Loading…
Jun-16-26 07:45AM	Scilex Holding Company Announces Dream Bowl I Meme Coin Tokens to List on Biconomy Exchange as Early as June 23, 2026 (GlobeNewswire) +18.79%
Jun-12-26 07:45AM	Scilex Holding Company ("Scilex") Confirms the Previously Announced Payment Date of June 15, 2026 for the Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity Securities (GlobeNewswire)
Jun-04-26 09:00AM	Scilex Holding Company ("Scilex") Announces a Payment Date of June 15, 2026 for the Previously Announced Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity Securities (GlobeNewswire) +5.72%
May-22-26 01:15PM	Scilex Holding Company ("Scilex") Announces Its Board of Directors Approved a Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity Securities with a Record Date of June 1, 2026 (GlobeNewswire)
May-20-26 09:11AM	Wellgistics Health and Datavault AI to Form DelivMeds AI via PharmacyChain License Expansion and Acquisitions of QOLPOM Biometric Health Data and Drone Logistics IP and Majority of Tollo Health (Business Wire)
May-15-26 08:02AM	Datavault AI posts 443% revenue jump, reiterates $200M full-year target (Investing.com)
May-05-26 01:00PM	Scilex Holding Company Announces Its Subsidiaries, ACEA Therapeutics, Inc. and ACEA Pharma, Inc., Entered into a Definitive Agreement with Phoenix Asia Holdings Limited (GlobeNewswire)
May-04-26 06:00AM	Scilex Holding Company Announces Its Board of Directors Approved May 26, 2026 as the Payment Date of the Previously Announced Dividend of Dream Bowl Meme Coin I Tokens to Record Holders of Common Stock and other Eligible Equity Securities as of the Record Date of April 30, 2026 (GlobeNewswire) +5.39%
Apr-27-26 08:45AM	Datavault AI Announces Execution of Binding Term Sheet for $120 Million Cash Contribution From Scilex Holding Company to Fund 100-City GPU Expansion of Quantum-Ready SanQtum Platform (Business Wire)
Apr-20-26 09:00AM	Scilex Holding Company Announces Its Board of Directors Approved a Dividend of Dream Bowl I Meme Coin Tokens to Holders of Common Stock and other Eligible Equity Securities with a Record Date of April 30, 2026 (GlobeNewswire)
11:16AM	Loading…
Mar-13-26 11:16AM	Scilex Holding Company Files Federal Securities Fraud Lawsuit Seeking Recovery of Approximately Ninety-Six (96) Million Misappropriated Collateral Shares of Datavault AI, Inc. from Marc Wade, The St. James Bank & Trust Company Ltd., Omega & Corinth Group Ltd., The Bank of New York Mellon Corporation, and Related Parties (GlobeNewswire) -6.02%
Jan-30-26 09:00AM	Scilex Holding Company Announces $20 Million Strategic Investment in Quantum Scan Holdings, Inc., Targeting Trillion-Dollar Preventive Diagnosis and Prognosis Markets (GlobeNewswire)
Jan-02-26 09:00AM	Scilex Holding Company Appoints Kasowitz LLP as Litigation and Intellectual Property Counsel (GlobeNewswire) +7.30%
Dec-23-25 09:00AM	Scilex Holding Company Confirms Dream Bowl 2026 Meme Coin Claim Process on December 24, 2025 Drop by Datavault AI Inc. (GlobeNewswire) -8.20%
Nov-26-25 06:00AM	Scilex Holding Company Announces Closing of Previously Announced Second Tranche Investment in Datavault AI Inc., Completing Its Two-Tranche Equity Financing in Datavault AI Inc. (GlobeNewswire)
Nov-25-25 02:37PM	Scilex Holding Company Announces Closing of Exercise of Warrants for $20.3 Million Gross Proceeds (GlobeNewswire) -7.95%
Nov-24-25 06:00AM	Scilex Holding Company Announces Exercise of Warrants for $20.3 Million Gross Proceeds (GlobeNewswire)
Nov-21-25 03:59PM	Scilex Holding Company Announces Update Regarding Distribution of Dream Bowl 2026 Meme Coin by Datavault AI Inc. (GlobeNewswire) +18.79%
Nov-20-25 07:06PM	Datavault AI Just Raised Guidance by 400%-Are You Paying Attention? (MarketBeat) +10.30%
Nov-18-25 12:07PM	Datavault AI Aims For $200 Million In 2026 (GuruFocus.com) +5.54%
Nov-11-25 09:30AM	Scilex Holding Company Announces that the Board of Directors of Datavault AI Inc. Has Approved the Distribution of a Dream Bowl 2026 Meme Coin to All Eligible Scilex and Datavault AI Stockholders of Record and Set a Record Date of November 25, 2025 (GlobeNewswire)
08:11AM	Datavault AI's 314% Upside: Huge Potential or Wall Street Mirage? (MarketBeat)
Nov-04-25 06:00AM	Scilex Holding Company Announces Worldwide Exclusive License for Tokenization and Monetization of Real-World Asset (RWA) in Genomic, DNA Data, Diagnosis, Therapeutics Products, Genetic and Drug information from Datavault AI (GlobeNewswire) +10.41%
Nov-03-25 09:53AM	Scilex Holding Company Announces the Sponsorship of Dream Bowl 2026 and Set a Record Date of November 14, 2025 for Its Shareholders to Receive Dream Bowl 2026 Meme Coin Distributed by DataVault AI (GlobeNewswire) +8.24%
Oct-02-25 03:00PM	Datavault AI (DVLT) Signs MOU With Korea Aerospace University to Advance Digital Credentialing, Aerospace Innovation (NewMediaWire) -16.10%
07:33PM	Loading…
Oct-01-25 07:33PM	Datavault AI: The New AI Contender Backed by Big Funding (MarketBeat) +5.08%
09:00AM	Scilex Holding Company Announces the Completion of the First Tranche of the Oramed Pharmaceuticals, Inc. Warrant Repurchase (GlobeNewswire)
Sep-26-25 04:12PM	Datavault AI Announces Closing of Initial Tranche Investment from Scilex Holding Company (Business Wire) -8.87%
03:57PM	Scilex Holding Company Announces Closing of Previously Announced Initial Tranche Investment in Datavault AI (GlobeNewswire)
01:52PM	This Penny Stock Is Surging on Supercomputer and Bitcoin Plans. Should You Buy It Now? (Barchart)
Sep-25-25 04:06PM	Datavault AI Secures $150 Million Strategic Investment from Scilex Holding Company to Build Supercomputer and Launch Independent Data Exchanges in the US (Business Wire)
03:45PM	Scilex Holding Company Announces $150 Million Strategic Bitcoin Investment in Datavault AI (GlobeNewswire)
06:00AM	Scilex Announces Closing of Previously Announced Non-Dilutive Value Enhancing Transaction with an Institutional Investor for the Exchange of $200 Million of Common Stock of Semnur Pharmaceuticals, Inc. Held by Scilex Holding Company for $200 Million in Bitcoin (GlobeNewswire)
Sep-24-25 10:11AM	Scilex Holding Company Announces It Has Entered into a Memorandum of Understanding with Biconomy.com to Collaborate on Future Cryptocurrency Strategies and Treasury Management (GlobeNewswire)
Sep-23-25 10:00AM	Scilex Holding Company Announces Signing of a Securities Purchase Agreement with an Institutional Investor to Exchange $200 Million of Common Stock of Semnur Pharmaceuticals, Inc. Held By Scilex Holding Company for $200 Million in Bitcoin (GlobeNewswire)
Sep-22-25 03:49PM	Semnur Pharmaceuticals, Inc. ("Semnur"), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, "Scilex"), and Denali Capital Acquisition Corp. Announce the Closing of Their Previously Announced Business Combination (GlobeNewswire)
Sep-04-25 09:00AM	Semnur Pharmaceuticals, Inc. ("Semnur"), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, "Scilex"), and Denali Capital Acquisition Corp. Announce Approval from Denali's Shareholders of the Previously Announced Business Combination (GlobeNewswire) +8.06%
Aug-21-25 06:00AM	Scilex Holding Company (Nasdaq: SCLX) Announces Its Majority-Owned Subsidiary, Semnur Pharmaceuticals, Inc. ("Semnur"), and Denali Capital Acquisition Corp. Have Entered into a Purchase Agreement with an Investor for a $20 Million Private Placement at $16.00 per share and Jaisim Shah, Scilex's CEO and President, Will be Dedicated to Semnur on a Full Time Basis to Rapidly Advance SP-102 to Regulatory Approval and Commercialization for the Treatment of Lumbosacral Radicular Pain (LRP)/Sciatica (GlobeNewswire)
Aug-13-25 06:00AM	Scilex Holding Company (Nasdaq: SCLX) Announces Effectiveness of Registration Statement on Form S-4 for the Proposed Business Combination of Denali Capital Acquisition Corp. and Semnur Pharmaceuticals, Inc., a Majority-Owned Subsidiary of Scilex (GlobeNewswire) +18.85%
Jun-23-25 04:50PM	Scilex Holding Company Announces Deferral of Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from May 2, 2025 to a future date to be determined by the Board (GlobeNewswire) +10.44%
Jun-05-25 12:05PM	Scilex Holding Company Announces Publication on GLOPERBA Dosing Adjustments in Peer-Review Journal (GlobeNewswire) -7.17%
May-16-25 09:00AM	Scilex Holding Company Presented Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL (GlobeNewswire)
May-01-25 09:00AM	Scilex Holding Company to Present Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL. (GlobeNewswire) +7.59%
Apr-30-25 01:46PM	Scilex Holding Company Regains Compliance with NASDAQ Minimum Bid Price Rule (GlobeNewswire)
Apr-22-25 09:00AM	Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from April 11, 2025 to May 2, 2025 (GlobeNewswire) -15.11%
Apr-16-25 02:12PM	Scilex Holding Company Announces FDA Has Approved Our Request for the Orphan Drug Designation for Colchicine for the Treatment of Pericarditis (GlobeNewswire) -11.56%
Apr-15-25 09:00AM	Scilex Holding Company Announces Approval of a New Drug Submission (NDS) from the Health Canada's Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for ELYXYB 's Acute Treatment of Migraine With or Without Aura in Canada (GlobeNewswire)
Apr-12-25 09:51AM	Scilex downgraded to Hold from Buy at D. Boral Capital (TipRanks)
Apr-11-25 09:00AM	Scilex Holding Company Announces 1-for-35 Reverse Stock Split (GlobeNewswire) -21.53%
Mar-26-25 08:24PM	Scilex Holding Company Has Appealed Lower Court Decision to the U.S. Court of Appeals for the Federal Circuit in Washington, DC and Will Continue to Vigorously Pursue its Infringement Action Against Aveva (GlobeNewswire)
Mar-10-25 09:00AM	Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from January 28, 2025 to April 11, 2025 (GlobeNewswire)
Jan-31-25 09:00AM	Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to April 14, 2025 (GlobeNewswire) -6.39%
Jan-22-25 08:00AM	Scilex Holding Company Announces that the U.S. FDA Has Acknowledged the Submission of Our Supplemental New Drug Application for ELYXYB in Acute Pain Indication (GlobeNewswire)
Jan-21-25 11:49AM	Scilex Holding Company Announces that It Regains Nasdaq Compliance Under Listing Rule 5250(c)(1) (GlobeNewswire) -5.79%
09:46AM	Scilex Holding Company Announces Extension of the Maturity Date of its Secured Promissory Note Issued to Oramed Pharmaceuticals Inc. to December 31, 2025 (GlobeNewswire)
09:00AM	Scilex Holding Company Announces that Its Note Holders Intend to Participate in the Funding and Licensing of Gloperba Ex-U.S. Commercialization Rights from Romeg Therapeutics, LLC (GlobeNewswire)
07:00AM	Scilex Holding Company Announces that It Will Be Filing Today of a Supplemental New Drug Application with the FDA for ELYXYB in Acute Pain Indication (GlobeNewswire)
06:00AM	Scilex Holding Company Announces Filing of its Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2024 (GlobeNewswire)
Jan-16-25 03:38PM	Scilex Holding Company Amends its License Agreement with Romeg Therapeutics, LLC, For the Worldwide Rights to Commercialize Gloperba , an FDA-Approved Prophylactic Treatment for Painful Gout Flares in Adults (GlobeNewswire) +5.25%
Jan-14-25 09:22AM	Scilex announces Pain Medicine News published data on ZTildo vs Lidocaine 5% (TipRanks)
Jan-13-25 09:00AM	Scilex Holding Company Announces Pain Medicine News Published Retrospective Claims Data on ZTlido vs. Lidocaine 5% Patch (GlobeNewswire)
Jan-08-25 04:00PM	Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination (GlobeNewswire) -5.77%
Dec-30-24 09:00AM	Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from November 7, 2024 to January 28, 2025 (GlobeNewswire) +7.97%
Dec-16-24 09:00AM	Scilex Holding Company Announces Early Installment Payment on its Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation (GlobeNewswire)
Dec-13-24 12:23PM	Scilex Holding Company Announces Closing of $17 Million Registered Direct Offering (GlobeNewswire)
Dec-12-24 08:21AM	Scilex Holding Company Announces $17 Million Registered Direct Offering (GlobeNewswire) -12.75%
Dec-11-24 12:49PM	Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports KDS2010 a Novel Oral Tablet Phase 2 Trial for Alzheimer's Disease (AD) Currently Enrolling with U.S. Patient Cohort to be Added in 2025 (GlobeNewswire)
07:30AM	Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports Phase 2 Trial for Obesity Currently Enrolling with U.S. Patient Cohort to be Added in 2025. Scilex Bio Reports Positive Results from the Recently Completed Phase 1 Trials Conducted by NeuroBiogen for KDS2010, a Novel Oral Tablet Recently Synthesized Potent, Selective, and Reversible Monoamine Oxidase B inhibitor (GlobeNewswire)
Dec-10-24 08:00AM	NeuroBiogen Company and Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company enter into Binding Term Sheet for Worldwide License, Along with the Rights to Sublicense for All of KDS2010 indications; Binding Term Sheet Includes Collaboration for Development and Commercialization of Novel Oral Tablet KDS2010 in Ongoing Phase 2 CardioMetabolic and Neurodegenerative Diseases (GlobeNewswire) -16.36%
07:00AM	Scilex Holding Company Enters into a Binding Term Sheet for a Joint Venture with IPMC and Bio Open Innovation Consortium to Develop and Commercialize a Phase 2 Clinical Stage, Potential Best-In-Class Novel Oral Tablet for the Treatment of Obesity and Neurodegenerative Diseases Including Alzheimer's Disease (GlobeNewswire)
Nov-22-24 06:00AM	Scilex Holding Company Announces Receipt of Notice from Nasdaq (GlobeNewswire) -5.57%
Nov-15-24 09:00AM	Scilex Holding Company Announces Presentation of Data at the 2024 American College of Rheumatology Convergence Conference to be held at the Walter E. Washington Convention Center in Washington, D.C. on November 14 19, 2024 (GlobeNewswire) -10.31%
Nov-11-24 05:01PM	Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination (GlobeNewswire) -9.01%
Nov-06-24 12:24PM	Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Announces Today the Filing of a Registration Statement on Form S-4 by Denali Capital Acquisition Corp. with the Securities and Exchange Commission Relating to the Previously Announced Proposed Business Combination Between Semnur and Denali (GlobeNewswire)
Oct-30-24 06:00AM	Scilex Pharmaceuticals Inc, a Wholly Owned Subsidiary of Scilex Holding Company, Announces Successful End of Phase II Meeting with FDA Leading to an Agreed Path Forward to NDA Upon Completion of Phase III Trials for Blockbuster Product Candidate, SP-103 (Lidocaine Topical System) 5.4%, a Next-Generation, Triple-Strength Formulation of ZTlido, for the Treatment of Chronic Neck Pain Associated with Muscle Spasms (GlobeNewswire) -5.35%
Oct-29-24 06:00AM	Scilex Holding Company, Following its Prior Announcement of the Record Date for a Dividend of Preferred Stock, Reiterates Information Previously Provided to Scilex Stockholders Regarding Manipulative and Naked Short Selling of Scilex Common Stock (GlobeNewswire)
Oct-28-24 06:00AM	Scilex Holding Company sets November 7, 2024 as the Record Date for a Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary (GlobeNewswire) +14.05%
Oct-16-24 07:00AM	Scilex Holding Company Announces that its Board of Directors has Authorized Management to Explore Ways to Maximize the Value of its Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., including by way of conducting a spinoff or public listing of securities of Scilex Pharmaceuticals Inc. Scilex Pharmaceuticals Commercial Products Include Three Non-Opioid Approved Products and Pipeline of Phase 3 Ready SP-103 With Greater Than a $1.0 Billion Revenue Potential (GlobeNewswire) +7.67%
04:00AM	Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Provides Timing to File in October 2024 a Registration Statement on Form S-4 with the SEC relating to the Previously Announced Proposed Business Combination Between Semnur and Denali with a Pre-Transaction Equity Value of $2.5 Billion (GlobeNewswire)
Oct-08-24 01:58PM	Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results for the Quarter Ended September 30, 2024 (GlobeNewswire) -8.34%
11:50AM	Scilex Holding Company Announces Closing of a $50 Million Registered Convertible Financing (GlobeNewswire)
Oct-07-24 10:00AM	Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt (PR Newswire) -6.55%
09:52AM	Scilex Holding Company Announces Signing of a $50 Million Registered Convertible Financing to Refinance and Restructure Existing Debt & Further Strengthens Financial Profile (GlobeNewswire)
Sep-26-24 09:00AM	Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to January 31, 2025 (GlobeNewswire) +12.51%
Sep-18-24 09:00AM	Scilex Holding Company Announces the Continuing Support from Endeavor Distribution LLC in the Multi-Year Agreement for Scilex's Commercial Products and the Satisfaction of FSF 33433 LLC $10 Million Loan (GlobeNewswire)
Sep-12-24 09:00AM	Scilex Holding Company Announces It Has Received the Drug Distributor Accreditation from the National Association of Boards of Pharmacy (NABP ) (GlobeNewswire)
Sep-09-24 09:00AM	Scilex Holding Company to Present at the 26th Annual H.C. Wainwright Global Investment Conference (GlobeNewswire)
Sep-05-24 09:00AM	Scilex Holding Company Announces Acceptance of Presentation at the 2024 American College of Rheumatology Convergence Conference to be held at the Walter E. Washington Convention Center in Washington, D.C. on November 14 19, 2024 (GlobeNewswire)
Sep-03-24 09:00AM	Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Announce Signing of a Merger Agreement for a proposed Business Combination (GlobeNewswire)
09:00AM	Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Announce Signing of a Merger Agreement for a proposed Business Combination, Providing for a Pre-Transaction Equity Value of Semnur of $2.5 Billion (GlobeNewswire)
Aug-30-24 09:00AM	Scilex Holding Company to Present Oral, Poster Presentations and Symposia on ZTlido (lidocaine topical system) at the 2024 Annual PAINWeek Conference in Las Vegas, NV on September 3-5, 2024 (GlobeNewswire)
Aug-29-24 09:00AM	Scilex Holding Company Announces FDA Final Approval to Precision Dosing for GLOPERBA Label (GlobeNewswire)
Aug-21-24 09:00AM	Scilex Holding Company Announces the U.S. Patent and Trademark Office Will Be Issuing New ELYXYB Patent Related to the Treatment of Acute Pain (GlobeNewswire)
Aug-09-24 09:00AM	Scilex Holding Company Enters into Master Distributor Agreement Among CH Trading Group and Devart Middle East for the Distribution of ZTlido in Morocco, Tunisia, Libya, Jordan, Iraq, and South Africa (GlobeNewswire)
Aug-01-24 09:00AM	Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results for the Month Ended July 31, 2024 (GlobeNewswire) -5.66%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Scilex Holding Co	10% Owner	Dec 30 '25	Sale	0.54	9,657,300	5,209,148	244,445,260	Dec 30 08:24 PM
Scilex Holding Co	10% Owner	Dec 29 '25	Sale	0.66	7,310,984	4,792,350	254,102,560	Dec 30 08:24 PM
Scilex Holding Co	10% Owner	Dec 26 '25	Sale	0.75	3,689,016	2,770,082	261,413,544	Dec 30 08:24 PM

Scilex Holding Co. engages in the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. Its products include ZTLido, Elyxyb, and Gloperba. The company was founded on February 21, 2020 and is headquartered in Palo Alto, CA.

CEODr. Henry H. Ji Ph.D.

Senior VPMr. Stephen Ma

Interim Chief Technical Officer & Senior VPDr. Suketu D. Desai Ph.D.

VP & Chief People OfficerMs. Gigi DeGuzman

Senior VPMr. Suresh K. Khemani

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SCLX

Scilex Holding Company

Upgrade your Finviz experience